Explore

Trendline Trendline
Ascendis Pharma Shifts Focus Back to Rare Endocrinology Amid Cancer Strategy Setback

Ascendis Pharma Shifts Focus Back to Rare Endocrinology Amid Cancer Strategy Setback

Ascendis Pharma Shifts Focus Back to Rare Endocrinology Amid Cancer Strategy Setback
Trendline Trendline
AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum
Trendline Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Trendline Trendline
Gilead Sciences Implements Major Workforce Reductions at Arcellx Following Acquisition

Gilead Sciences Implements Major Workforce Reductions at Arcellx Following Acquisition

Gilead Sciences Implements Major Workforce Reductions at Arcellx Following Acquisition
Trendline Trendline
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in May 2026
Trendline Trendline
Viridian Therapeutics Prices $350 Million Public Offerings for Expansion

Viridian Therapeutics Prices $350 Million Public Offerings for Expansion

Viridian Therapeutics Prices $350 Million Public Offerings for Expansion
Trendline Trendline
AN2 Therapeutics to Present at 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Present at 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Present at 2026 Stifel Virtual Targeted Oncology Forum
Trendline Trendline
Exelixis to Webcast Fireside Chats at Major Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Major Investor Conferences in May 2026

Exelixis to Webcast Fireside Chats at Major Investor Conferences in May 2026
Trendline Trendline
Soligenix Emphasizes Patient-Centric Drug Development Through Reformulation

Soligenix Emphasizes Patient-Centric Drug Development Through Reformulation

Soligenix Emphasizes Patient-Centric Drug Development Through Reformulation
Trendline Trendline
ParcelBio Secures $13M to Advance Programmable mRNA Platform for Durable Medicines

ParcelBio Secures $13M to Advance Programmable mRNA Platform for Durable Medicines

ParcelBio Secures $13M to Advance Programmable mRNA Platform for Durable Medicines
Trendline Trendline
Atossa Therapeutics Reports Q1 2026 Financial Results and Strategic Developments

Atossa Therapeutics Reports Q1 2026 Financial Results and Strategic Developments

Atossa Therapeutics Reports Q1 2026 Financial Results and Strategic Developments
Trendline Trendline
Immunai Expands Collaboration with AstraZeneca in $37.5 Million Deal for Oncology Development

Immunai Expands Collaboration with AstraZeneca in $37.5 Million Deal for Oncology Development

Immunai Expands Collaboration with AstraZeneca in $37.5 Million Deal for Oncology Development